261 related articles for article (PubMed ID: 32207067)
21. The safety of brodalumab for the treatment of psoriasis.
Iznardo H; Puig L
Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
[No Abstract] [Full Text] [Related]
22. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
Yamaguchi Y; Takatsu N; Ootaki K; Nakagawa H
J Dermatol; 2020 Jun; 47(6):569-577. PubMed ID: 32275086
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
24. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
26. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
Reich K; Hansen JB; Puig L; Konstantinou MP; Warren RB
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2034-2044. PubMed ID: 34076919
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Timmermann S; Hall A
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
Reich K; Iversen L; Puig L; Lambert J; Mrowietz U; Kaplan Saday K; Warren RB
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1275-1283. PubMed ID: 35279890
[TBL] [Abstract][Full Text] [Related]
29. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies.
Zachariae C; Mrowietz U; Strodl Andersen J; Puig L
Eur J Dermatol; 2022 Jul; 32(4):530-535. PubMed ID: 36301758
[TBL] [Abstract][Full Text] [Related]
30. Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2027-2042. PubMed ID: 34606048
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
Elewski B; Rich P; Lain E; Soung J; Lewitt GM; Jacobson A
J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).
Papp K; Menter A; Leonardi C; Soung J; Weiss S; Pillai R; Jacobson A
Br J Dermatol; 2020 Dec; 183(6):1037-1048. PubMed ID: 32286683
[TBL] [Abstract][Full Text] [Related]
33. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
[TBL] [Abstract][Full Text] [Related]
35. A Case of Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome during Treatment with Brodalumab for Generalized Pustular Psoriasis.
Okazaki S; Hoashi T; Saeki H; Kanda N
J Nippon Med Sch; 2021; 88(6):569-573. PubMed ID: 34980743
[TBL] [Abstract][Full Text] [Related]
36. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
37. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
38. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).
Blauvelt A; Papp KA; Lebwohl MG; Green LJ; Hsu S; Bhatt V; Rastogi S; Pillai R; Israel R
J Am Acad Dermatol; 2017 Aug; 77(2):372-374. PubMed ID: 28711089
[No Abstract] [Full Text] [Related]
39. Brodalumab for the treatment of plaque psoriasis: up-to-date.
Beck KM; Koo J
Expert Opin Biol Ther; 2019 Apr; 19(4):287-292. PubMed ID: 30831036
[TBL] [Abstract][Full Text] [Related]
40. Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Farahnik B; Beroukhim K; Abrouk M; Nakamura M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
Dermatol Ther (Heidelb); 2016 Jun; 6(2):111-24. PubMed ID: 27221323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
